Trials / Withdrawn
WithdrawnNCT00615524
Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Compare the Efficacy and Tolerability of Pazopanib Administered in Combination With Exemestane Versus Exemestane Plus Placebo in Postmenopausal Subjects With Advanced or Metastatic Hormone Receptor Positive Breast Cancer
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to compare the efficacy and safety of exemestane alone or in combination with pazopanib in postmenopausal women who have hormone receptor positive breast cancer and have failed therapy with tamoxifen, anastrazole or letrozole.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | exemestane and pazopanib |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2012-11-01
- Completion
- 2012-11-01
- First posted
- 2008-02-14
- Last updated
- 2018-01-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00615524. Inclusion in this directory is not an endorsement.